CN115701988A - 阿卡他定和皮质类固醇的组合 - Google Patents

阿卡他定和皮质类固醇的组合 Download PDF

Info

Publication number
CN115701988A
CN115701988A CN202180040805.7A CN202180040805A CN115701988A CN 115701988 A CN115701988 A CN 115701988A CN 202180040805 A CN202180040805 A CN 202180040805A CN 115701988 A CN115701988 A CN 115701988A
Authority
CN
China
Prior art keywords
fluticasone
alcaftadine
composition
topical composition
corticosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180040805.7A
Other languages
English (en)
Chinese (zh)
Inventor
乌尔哈斯·杜帕德
阿希莱什·夏尔马
巴巴萨海布·阿瓦雷
威拉·沙阿
阿莫尔·艾瓦勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arkham Laboratories Ltd
Original Assignee
Arkham Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arkham Laboratories Ltd filed Critical Arkham Laboratories Ltd
Publication of CN115701988A publication Critical patent/CN115701988A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180040805.7A 2020-06-15 2021-06-14 阿卡他定和皮质类固醇的组合 Pending CN115701988A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921053286 2020-06-15
IN201921053286 2020-06-15
PCT/IB2021/055222 WO2021255622A1 (en) 2020-06-15 2021-06-14 Combination of alcaftadine and a corticosteroid

Publications (1)

Publication Number Publication Date
CN115701988A true CN115701988A (zh) 2023-02-14

Family

ID=76523259

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180040805.7A Pending CN115701988A (zh) 2020-06-15 2021-06-14 阿卡他定和皮质类固醇的组合

Country Status (12)

Country Link
US (1) US20230218630A1 (cg-RX-API-DMAC7.html)
EP (1) EP4164614A1 (cg-RX-API-DMAC7.html)
JP (1) JP7791119B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230024928A (cg-RX-API-DMAC7.html)
CN (1) CN115701988A (cg-RX-API-DMAC7.html)
AU (1) AU2021291684A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024840A2 (cg-RX-API-DMAC7.html)
CA (1) CA3181959A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003534A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022015965A (cg-RX-API-DMAC7.html)
WO (1) WO2021255622A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202212128B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
CN115485027A (zh) 2020-03-24 2022-12-16 思瑞诺医疗有限公司 冠状病毒感染引起的化学感觉功能障碍的治疗
US20240173331A1 (en) * 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
AU2023204805A1 (en) * 2022-01-06 2024-07-25 Cyrano Therapeutics, Inc. Improved nasal administration of pharmaceutical formulations
WO2024228988A2 (en) * 2023-05-02 2024-11-07 Cyrano Therapeutics, Inc. Treatment for taste and smell loss
GR1010821B (el) * 2023-11-09 2024-11-15 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Σταθερο ομογενοποιημενο φαρμακευτικο ρινικο εναιωρημα συνδυασμου αζελαστινης και φλουτικαζονης

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468743A (en) * 1991-06-13 1995-11-21 Janssen Pharmaceutica N.V. Imidazo[2,1-b]benzazepine derivatives, compositions and method of use
WO2011141929A2 (en) * 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
CN102283849A (zh) * 2011-06-29 2011-12-21 北京阜康仁生物制药科技有限公司 一种含有阿卡他定的药物组合物
US20150079178A1 (en) * 2013-09-13 2015-03-19 Glenmark Pharmaceuticals Limited Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US20170065605A1 (en) * 2006-03-31 2017-03-09 Vistakon Pharmaceuticals, Llc Treatments of ocular allergy with alcaftadine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE84968T1 (de) 1987-11-13 1993-02-15 Asta Medica Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
DE19947234A1 (de) 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
ATE317268T1 (de) 2001-12-05 2006-02-15 Alcon Inc Verwendung eines h1-antagonisten und von rimexolon als sicheres steroid zur behandlung von rhinitis
PT1919450E (pt) 2005-09-01 2014-09-10 Meda Ab Composição lipossomal contendo anti-histamínico e corticosteróide e sua utilização para a preparação de um medicamento para o tratamento de rinite e distúrbios relacionados
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
RU2652352C2 (ru) * 2012-12-17 2018-04-25 Глаксо Груп Лимитед Комбинация левокабастина и флутиказона фуроата для лечения воспалительных и/или аллергических состояний
JP7191022B2 (ja) 2017-07-28 2022-12-16 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468743A (en) * 1991-06-13 1995-11-21 Janssen Pharmaceutica N.V. Imidazo[2,1-b]benzazepine derivatives, compositions and method of use
US20170065605A1 (en) * 2006-03-31 2017-03-09 Vistakon Pharmaceuticals, Llc Treatments of ocular allergy with alcaftadine
WO2011141929A2 (en) * 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
CN102283849A (zh) * 2011-06-29 2011-12-21 北京阜康仁生物制药科技有限公司 一种含有阿卡他定的药物组合物
US20150079178A1 (en) * 2013-09-13 2015-03-19 Glenmark Pharmaceuticals Limited Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine

Also Published As

Publication number Publication date
KR20230024928A (ko) 2023-02-21
MX2022015965A (es) 2023-03-14
EP4164614A1 (en) 2023-04-19
WO2021255622A1 (en) 2021-12-23
ZA202212128B (en) 2024-04-24
US20230218630A1 (en) 2023-07-13
JP2023530166A (ja) 2023-07-13
JP7791119B2 (ja) 2025-12-23
CA3181959A1 (en) 2021-12-23
BR112022024840A2 (pt) 2022-12-27
AU2021291684A1 (en) 2022-12-08
CL2022003534A1 (es) 2023-06-23

Similar Documents

Publication Publication Date Title
JP7791119B2 (ja) アルカフタジンとコルチコステロイドの組み合わせ
EP2522365B1 (en) Compositions comprising azelastine and methods of use thereof
JP5683719B2 (ja) ベポタスチン組成物
US12274702B2 (en) Nasal compositions comprising alcaftadine
US20090022671A1 (en) Treatment methods
US20120022032A1 (en) Corticosteroid compositions and methods of treatments thereof
US20150080355A1 (en) Pharmaceutical Compositions Comprising Ebastine and Fluticasone
RU2854644C1 (ru) Композиции для интраназального применения, содержащие алкафтадин
WO2015009776A1 (en) Low dose corticosteroid microemulsion compositions and methods of treatments thereof
WO2006097458A1 (en) Novel combination
RU2687551C2 (ru) Стабильная фармацевтическая композиция с фиксированной дозой, содержащая мометазон и олопатадин
NZ620005B2 (en) Pharmaceutical composition comprising ebastine and fluticasone

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination